Imatinib as a paradigm of targeted therapies

Advances in Cancer Research

Volumn 91, Issue , 2004, Pages 1-30

  Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GENETICS; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; EXPERIMENTAL MODEL; GASTROINTESTINAL STROMAL TUMOR; GENE MAPPING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; HYPEREOSINOPHILIC SYNDROME; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; NONHUMAN; ONCOGENE; PATHOGENESIS; PHARMACODYNAMICS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN TARGETING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

EID: 4344623889     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(04)91001-9     Document Type: Article

References (102)

1. Abelson H.T., Rabstein L.S. Lymphosarcoma: Virus-induced thymic-independent disease in mice. Cancer Res. 30:1970;2213-2222
2. Al-Ali H.-K., Heinrich M.C., Lange T., Krahl R., Mueller M., Mueller C., Niederwieser D., Druker B.J., Deininger M.W. High incidence of BCR-ABL kinase domain mutations in CML patients with secondary resistance to imatinib. Hematol. J. 5:2004;55-60
3. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., Dimitrijevic S., Mahon F.X., Marin D., Nikolova Z., Olavarria E., Silberman S., Schultheis B., Cross N.C., Goldman J.M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β N. Engl. J. Med. 347:2002;481-487
4. Barthe C., Gharbi M.J., Lagarde V., Chollet C., Cony-Makhoul P., Reiffers J., Goldman J.M., Melo J.V., Mahon F.X. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br. J. Haematol. 119:2002;109-111
5. Ben-Neriah Y., Daley G.Q., Mes-Masson A.-M., Witte O.N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcrabl hybrid gene. Science. 233:1986;212-214
6. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinb. Med. Surg. J. 64:1845;413-423
7. r 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4:1998;1661-1672
8. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCRABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99:2002;3472-3475
9. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., Taylor K., Herrmann R., Seymour J.F., Arthur C., Joske D., Lynch K., Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102:2003;276-283
10. Buchdunger E., Zimmermann J., Mett H., Meyer T., Müller M., Druker B.J., Lydon N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104
11. Buchdunger E., Matter A., Druker B.J. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim. Biophys. Acta. 1551:2001;M11-M18
12. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The Tel platelet-derived growth factor β receptor (PDGF-β-R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF-β-R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA. 93:1996;14845-14850
13. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N.B., Gilliland D.G., Druker B.J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood. 90:1997;4947-4952
14. Chan L.C., Karhi K.K., Rayter S.I., Heisterkamp N., Eridani S., Powles R., Lawler S.D., Groffen J., Foulkes J.G., Greaves M.F., et al. A novel Abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature. 325:1987;635-637
15. Clark S.S., McLaughlin J., Crist W.M., Champlin R., Witte O.N. Unique forms of the Abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science. 235:1987;85-88
16. Clark S.S., McLaughlin J., Timmons M., Pendergast A.M., Ben-Neriah Y., Dow L.W., Crist W., Rovera G., Smith S.D., Witte O.N. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 239:1988;775-777
17. Collins S.J., Kubonishi I., Miyoshi I., Groudine M.T. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science. 225:1984;72-74
18. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:2003;1201-1214
19. Corbin A.S., Buchdunger E., Pascal F., Druker B.J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. 277:2002;32214-32219
20. Corbin A.S., La Rosée P., Stoffregen E., Druker B.J., Deininger M.W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 101:2003;4611-4614
21. Corless C.L., McGreevey L., Haley A., Town A., Heinrich M.C. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am. J. Pathol. 160:2002;1567-1572
22. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcrabl gene of the Philadelphia chromosome. Science. 247:1990;824-830
23. Davis R.L., Konopka J.B., Witte O.N. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-Abl proteins with similar in vitro kinase properties. Mol. Cell. Biol. 5:1985;204-213
24. Deininger M.W., Goldman J.M., Lydon N., Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 90:1997;3691-3698
25. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood. 96:2000;3343-3356
26. de Klein A., van Kessel A.G., Grosveld G., Bartram C.R., Hagemeijer A., Bootsma D., Spurr N.K., Heisterkamp N., Groffen J., Stephenson J.R. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature. 300:1982;765-767
27. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480
28. Druker B.J., Lydon N.B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105:2000;3-7
29. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat. Med. 2:1996;561-566
30. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001a;1038-1042
31. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001b;1031-1037
32. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: Biology and therapy. Ann. Intern. Med. 131:1999;207-219
33. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., Miettinen M., O'Leary T.J., Remotti H., Rubin B.P., Shmookler B., Sobin L.H., Weiss S.W. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum. Pathol. 33:2002;459-465
34. Gale R.P., Canaani E. An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA. 81:1984;5648-5652
35. + leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23:1997;380-394
36. Geary C.G. The story of chronic myeloid leukaemia. Br. J. Haematol. 10:2000;2-11
37. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1578
38. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316
39. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880
40. Griffin J.H., Leung J., Bruner R.J., Caligiuri M.A., Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. USA. 100:2003;7830-7835
41. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 36:1984;93-99
42. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-Kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000a;925-932
43. Heinrich M.C., Wait C.L., Yee K.W.H., Griffith D.J. STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis. Blood. 96:2000b;173b
44. Heinrich M.C., Rubin B.P., Longley B.J., Fletcher J.A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol. 33:2002;484-495
45. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., Kiese B., Eisenberg B., Roberts P.J., Singer S., Fletcher C.D., Silberman S., Dimitrijevic S., Fletcher J.A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:2003a;4342-4349
46. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003b;708-710
47. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., Groffen J. Acute leukaemia in bcrabl transgenic mice. Nature. 344:1990;251-253
48. Hermans A., Heisterkamp N., von Lindern M., van Baal S., Meijer D., van der Plas D., Wiedemann L.M., Groffen J., Bootsma D., Grosveld G. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell. 51:1987;33-40
49. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580
50. Hochhaus A., Kreil S., Corbin A.S., La Rosée P., Müller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C.P., Berger U., Gschaidmeier H., Druker B.J., Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16:2002;2190-2196
51. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 99:2001;1860-1862
52. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24:2000;57-60
53. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., Gathmann I., Bolton A.E., van Hoomissen I.C., Goldman J.M., Radich J.P. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349:2003;1423-1432
54. Hunter T., Cooper J.A. Protein-tyrosine kinases. Annu. Rev. Biochem. 54:1985;897-930
55. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., Silberman S., Capdeville R., Dimitrijevic S., Druker B. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:2001;1052-1056. D. D. G.
56. Johnson B.E., Fischer T., Fischer B., Dunlop D., Rischin D., Silberman S., Kowalski M.O., Sayles D., Dimitrijevic S., Fletcher C., Hornick J., Salgia R., Le Chevalier T. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 9:2003;5880-5887
57. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:2002;645-652
58. Kantarjian H.M., Keating M.J., Talpaz M., Walters R.S., Smith T.L., Cork A., McCredie K.B., Freireich E.J. Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients. Am. J. Med. 83:1987;445-454
59. Kasper B., Fruehauf S., Schiedlmeier B., Buchdunger E., Ho A.D., Zeller W.J. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor: Activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother. Pharmacol. 44:1999;433-438
60. Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCRABL. Proc. Natl. Acad. Sci. USA. 87:1990;6649-6653
61. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-Abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 37:1984;1035-1042
62. La Rosee P., Corbin A.S., Stoffregen E.P., Deininger M.W., Druker B.J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62:2002;7149-7153
63. le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In vivo eradication of human BCRABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91:1999;163-168
64. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082
65. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., McMahon G., Longley B.J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: Kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744
66. Magnusson M.K., Meade K.E., Nakamura R., Barrett J., Dunbar C.E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood. 100:2002;1088-1091
67. Maki R.G., Awan R.A., Dixon R.H., Jhanwar S., Antonescu C.R. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer. 100:2002;623-626
68. Marley S.B., Deininger M.W., Davidson R.J., Goldman J.M., Gordon M.Y. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp. Hematol. 28:2000;551-557
69. Mes-Masson A.-M., McLaughlin J., Daley G.Q., Paskind M., Witte O.N. Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA. 83:1986;9768-9772
70. Modi S., Seidman A., Dickler M., Moasser M., D'Andrea G., Moynahah M.E., Panageas K.S., Tan L., Norton L., Hudis C. A phase II trial of STI571 in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;18a
71. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243
72. Nardi V., Azam M., Daley G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11:2004;35-43
73. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science. 132:1960;1497
74. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes C., Cornelissen J., Fischer T., Hochhaus A., Hughes T., Kantarjian H., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson S., Gratwohl A., Goldman J.M., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348:2003;994-1004
75. Oda T., Heaney C., Hagopian J., Okuda K., Griffin J.D., Druker B.J. CRKL is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269:1994;22925-22928
76. Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers J., Silver R.T., Tura S., Fischer T., Deininger M.W., Schiffer C.A., Baccarani M., Gratwohl A., Hochhaus A., Hoelzer D., Fernandes-Reese S., Gathmann I., Capdeville R., O'Brien S.G. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 100:2002;1965-1971
77. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Clinical investigations of the pharmacokinetics and pharmacodynamics of imatinib in a phase 1 trial with chronic myeloid leukemia patients. J. Clin. Oncol. 22:2004;935-942
78. Rao K.V., Goodin S., Capanna T., Doyle-Lindrud S., Dipaola R.S. A phase II trial of imatinib mesylate in patients with PSA progression after local therapy for prostate cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;409a
79. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 100:2002;1014-1018
80. Rosenberg N., Witte O.N. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 35:1988;39-81
81. Rowley J.D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 243:1973;290-293
82. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D.M., Fletcher J.A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121
83. Rubin B.P., Schuetze S.M., Eary J.F., Norwood T.H., Mirza S., Conrad E.U., Bruckner J.D. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20:2002;3586-3591
84. Sacchi S., Kantarjian H.M., O'Brien S., Cortes J., Rios M.B., Giles F.J., Beran M., Koller C.A., Keating M.J., Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 86:1999;2632-2641
85. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340:1999;1330-1340
86. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., Schiffer C.A., Talpaz M., Guilhot F., Deininger M.W.N., Fischer T., O'Brien S.G., Stone R.M., Gambacorti-Passerini C.B., Russell N.H., Reiffers J.J., Shea T.C., Chapuis B., Coutre S., Tura S., Morra E., Larson R.A., Saven A., Peschel C., Gratwohl A., Mandelli F., Ben-Am M., Gathmann I., Capdeville R., Paquette R.L., Druker B.J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood. 99:2002;3530-3539
87. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942
88. Shah N.P., Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 22:2003;7389-7395
89. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125
90. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 315:1985;550-554
91. Simon M.P., Pedeutour F., Sirvent N., Grosgeorge J., Minoletti F., Coindre J.M., Terrier-Lacombe M.J., Mandahl N., Craver R.D., Blin N., Sozzi G., Turc-Carel C., O'Brien K.P., Kedra D., Fransson I., Guilbaud C., Dumanski J.P. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15:1997;95-98
92. Sjoblom T., Shimizu A., O'Brien K.P., Pietras K., Dal Cin P., Buchdunger E., Dumanski J.P., Ostman A., Heldin C.H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61:2001;5778-5783
93. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., Schiffer C.A., Fischer T., Deininger M.W.N., Lennard A.L., Hochhaus A., Ottmann O.G., Gratwohl A., Baccarani M., Stone R., Tura S., Mahon F.-X., Fernandes-Reese S., Gathmann I., Capdeville R., Kantarjian H.M., Sawyers C.L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood. 99:2002;1928-1937
94. Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., Fletcher C.D., Fletcher J.A., Demetri G.D. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene. 20:2001;5054-5058
95. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M., Silberman S., Nielsen O.S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet. 358:2001;1421-1423
96. Verweij J., van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der Graaf W., Radford J., Le Cesne A., Hogendoorn P.C., di Paola E.D., Brown M., Nielsen O.S. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer. 39:2003;2006-2011
97. Virchow R. Weisses Blut. Frorieps Notizen. 36:1845;151-156
98. von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet. 359:2002;487-491
99. Wyman K., Atkins M.B., Hubbard F., McDermott D., Kelley M., Ko Y.-L., Viar V., Mier J., Roberts S., Sosman J. A phase II trial of imatinib mesylate at 800 mg daily in metastatic melanoma: Lack of clinical efficacy with significant toxicity. Proc. Am. Soc. Clin. Onc. 22:2003;713a
100. Yaish P., Gazit A., Gilon C., Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 242:1988;933-935
101. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B., Traxler P. Phenylamino-pyrimidine (PAP) derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6:1996;1221-1226
102. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the Abl-kinase: Phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7:1997;187-192